madrid2i

Resumen

[0001] The invention relates to new compounds derived from 1,4-bis(alkylamino) benzo[g]phthalazenes of formula (I) which are useful as anticancerous and antiparasitic agents.

Reivindicaciones

1. A compound of the formula <img class="EMIRef" id="414580522-ib0010" /> wherein. The aryl moiety can be mono- or di-substituted at any feasible position(s) in the ring C (when q is 1 or 2 respectively) or it can be unsubstituted (when q is 0). R is lower alkyl, aryl, alkoxy, nitro, amino, alkylamino or acylamino group. R<1> and R<2> are the same or different and are each hydrogen atom, a lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, an heterocyclic ring linked to the nitrogens directly or by an alkyl chain linear or branched or R<1> and R<2> taken together with the nitrogen to which they are attached are pyrrolidino, piperidino, morfolino, piperazino, 4-alkylpiperazino or 4-arylpiperazino, or an 1,4-bis(amino)benzo[g]-phthalazinium salt of the formula <img class="EMIRef" id="414580522-ib0011" /> wherein Rq, R<1> and R<2> are as defined above, n is 1 or 2, X is hydrogen atom, methyl or ethyl group and Y" is chloride, bromide, iodide, an oxoacid anion or an organic anion. 2. A compound of claim 1 of the formula I wherein the aryl moiety is unsubstituted (q is 0), R<1> is hydrogen atom and R<2> is hydrogen atom, a lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or an heterocyclic ring linked to the nitrogens directly or by an alkyl chain linear or branched. 3. A compound of the claim 1 of the formula I wherein the aryl moiety is monosubstituted (q is 1), at the C-6 carbon and R is a lower alkyl, aryl, alkoxy, nitro, amino, alkylamino or an acylamino group. 4. A compound of the claims 1 and 3 of the formula I wherein R<1> is hydrogen atom and R<2> is hydrogen atom, a lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, or an heterocyclic ring linked to the nitrogens directly or by an alkyl chain linear or branded. 5. A compound of claims 1-4 of the formula II wherein the aryl moiety is unsubstituted (q is 0), X is hydrogen atom, a methyl or ethyl group, n is 1 or 2 and Y<n> is chloride, bromide, iodide an oxoacid anion or an organic acid anion. 6. A compound of claims 1-5 wherein the aryl moiety can be monosubstituted at the C-6 position in the ring C (when q is 1) or it can be unsubstituted (when q is 0), R is hydrogen, methoxy or dimethylamino, R<1> is hydrogen, and R<2> is hydrogen atom, an alkyl group comprised of 1 to 6 carbon atoms in linear, branched or cyclic configuration. 7. 1,4-bis(n-buthyalmino)benzo[g]phthalazine. 8. 1,4-bis(n-buthy!amino)-3(2)H-benzo[g]phtha!azinium chloride. 9. 1,4-bis(n-buthylamino)-6-methoxy-benzo[g]phthalazine. 10. 1,4-bis(n-buthylamino)-6-methoxi-benzo[g]phthalazinium chloride. 11. 1,4-bis(n-propylamino)-benzo[g]phthalazine. 12. 1,4-bis(n-propylamino)-3(2)H-benzo[g]phthalazinium chloride. 13. 1,4-bis(n-propylamino)-6-methoxy-benzo[g]phthalazine. 14. 1,4-bis(n-propylamino)-6-methoxy-3(2)H-benzo[g] phthalazinium chloride. 15. A pharmaceutical composition comprising a compound of any one of the preceding claims in a mixture with a pharmaceutical acceptable carrier. 16. A compound according to any one of claims 1 to 15 for use as a medicament for the cancer therapy. 17. A compound according to any one of claims 1 to 15 for use as a medicament for the Chagas' disease therapy. 18. A compound according to any one of claims 1 to 15 for use as a medicament for the trypanosomiasis and other Protozoan Diseases therapy. 19. A process for preparing a compound of the formula <img class="EMIRef" id="414580522-ib0012" /> wherein. The aryl moiety can be mono- or disubstituted at any feasible position(s) in the ring C (when q is 1 or 2 respectively) or it can be unsubstituted (when q is 0), R is lower alkyl, aryl, alkoxy, nitro, amino, alkylamino or an acylamino group. R<1> and R<2> are the same or different and are each hydrogen atom, a lower alkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, an heterocyclic ring linked to the nitrogens directly or by an alkyl chain linear or branched or R<1> and R<2> taken together with the nitrogen to which they are attached are pyrrolidino, piperidino, morfolino, piperazino, 4-alkylpiperazino or 4-arylpiperazino, which comprises reacting an 1,4- bis(amino)benzo[g]phthalazine of the formula <img class="EMIRef" id="414580522-ib0013" /> (wherein Rq, R<1> and R<2> are defined as above), with acids such as hydrochloric, sulfuric acid and the like or alkyl halides such as methyl or ethyl chloride. 20. A process according to claim 19 for preparing a compound of the formula II wherein the aryl moiety is unsubstituted (q is 0), X is hydrogen atom, a methyl or ethyl group, n is 1 or 2 and Y"- is chloride, bromide, iodide, an oxoacid anion or an organic acid anion. 21. A process according to claim 19 for preparing a compound of of the claims 19 or 20 wherein the aryl moiety can be monosubstituted at the C-6 position in the ring C (when q is 1) or it can be unsubstituted (when q is 0), R is hydrogen atom, a methoxy or dimethylamino group, R<1> is hydrogen, and R<2> is hydrogen atom, or an alkyl group comprised of 1 to 6 carbons in linear, branched or cyclic configuration. 22. A procedure according to claim 19 for preparing 1,4-bis (n-buthylamino)-3(2)H-benzo[g]phthalazinium chloride. 23. A procedure according to claim 19 for preparing 1,4-bis (n-buthylamino)-6-methoxy-3(2)H-benzo[g]-phthalazinium chloride. 24. A procedure according to claim 19 for preparing 1,4-bis (n-propylamino)-3(2)H-benzo[g]phthalazinium chloride. 25. A procedure according to claim 19 for preparing 1,4-bis (n-propylamino)-3(2)H-6-methoxy-benzo[g]-phthalazinium chloride. 26. Use of a compound of any one of claims 1-15 for preparing a medicament for treating cancer. 27. Use of a compound of any one of claims 1-15 for preparing a medicament for treating the Chagas' disease. 28. Use of a compound of any one of claims 1-15 for preparing a medicament for treating the trypanosomiasis and other Protozoan diseases. 29. Brief statement of amendment under article 19(1) 30. 1. The terms "alkoxyalkyl" and alkylaminoalkyl" which could invalidate the pertinent claims because said terms are related with the compounds published in the following articles have been deleted from the claims: - L. Campayo § P. Navarro. Eur. J. Med.Chem-Chim.Ther., 1986, 21, 143-149 and - L. Campayo, F.M. Cano, C. Foces-Foces § P. Navarro. J., Chem.Soc.Perkin Transll, 1987, 569-573. Once said terms have been deleted it would be inappropriate to delete claims 1-5 regarding the "compounds", as well as the one regarding a "pharmaceutical composition" (claim 15) which comprises a compound of the pertinent claims and even less, those in which "the use of a compound as a medication for cancer therapy" (claim 16) or "the use of a compound to prepare a medication for cancer treatment" (claim 26) is claimed. Therefore, the terms "alkoxyalkyl" and "alkylaminoalkyl" should be deleted from the specification. 31. 2. In the "process" claims for the contracting states GR, ES, all those process claims that could be considered "without novelty" because they are related to the Spanish process patent ES, A.533464 ("Consejo Superior de Investigaciones Cientfficas") 1 August 1985 (Authors: L. Campayo § P. Navarro) have been deleted. 32. 3. The following terms have been modified: - "cycloalkylalkylene" by "cycloalkylalkyl" - "alkylene" by "alkyl"

Índice de la ficha

En detalle

Resumen

Reivindicaciones

Etiquetas